Rezzonico Rossano, Caccamo Letizia M, Manfredini Valeria, Cartabia Massimo, Sanchez Nieves, Paredes Zoraida, Froesch Patrizia, Cavalli Franco, Bonati Maurizio
NICU Rho Az. Ospedaliera "G. Salvini" Garbagnate Milanese, Milan, Italy.
Department of Public Health, Laboratory for Mother and Child Health, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
BMC Pediatr. 2015 Mar 25;15:26. doi: 10.1186/s12887-015-0338-3.
The use of Nasal Continuous Positive Airway Pressure Ventilation (NCPAP) has begun to increase and is progressively replacing conventional mechanical ventilation (MV), becoming the cornerstone treatment for newborn respiratory distress syndrome (RDS). However, NCPAP use in Lower-Middle Income Countries (LMICs) is poor. Moreover, bubble NCPAP (bNCPAP), for efficacy, cost effectiveness, and ease of use, should be the primary assistance technique employed in newborns with RDS.
To measure the impact on in-hospital newborn mortality of using a bNCPAP device as the first intervention on newborns requiring ventilatory assistance.
Prospective pre-intervention and post-intervention study.
The largest Neonatal Intensive Care Unit (NICU) in Nicaragua.
In all, 230 (2006) and 383 (2008) patients were included.
In May 2006, a strategy was introduced to promote the systematic use of bNCPAP to avoid intubation and MV in newborns requiring ventilatory assistance. Data regarding gestation, delivery, postnatal course, mortality, length of hospitalisation, and duration of ventilatory assistance were collected for infants assisted between May and December 2006, before the project began, and between May and December 2008, two years afterwards.
The pre- vs post-intervention proportion of newborns who died in-hospital was the primary end point. Secondary endpoints included rate of intubation and duration of NICU stay.
Significant differences were found in the rate of intubation (72 vs 39%; p < 0.0001) and the proportion of patients treated exclusively with bNCPAP (27% vs 61%; p <0.0001). Mortality rate was significantly reduced (40 vs 23%; p < 0.0001); however, an increase in the mean duration of NICU stay was observed (14.6 days in 2006 and 17.5 days in 2008, p = 0.0481). The findings contribute to the evidence that NCPAP, particularly bNCPAP, is the first-line standard of care for efficacy, cost effectiveness, and ease of use in newborns with respiratory distress in LMICs.
This is the first extensive survey performed in a large NICU from a LMICs, proving the efficacy of the systematic use of a bNCPAP device in reducing newborn mortality. These findings are an incentive for considering bNCPAP as an elective strategy to treat newborns with respiratory insufficiency in LMICs.
鼻持续气道正压通气(NCPAP)的使用已开始增加,并逐渐取代传统机械通气(MV),成为新生儿呼吸窘迫综合征(RDS)的基础治疗方法。然而,中低收入国家(LMICs)对NCPAP的使用情况不佳。此外,由于有效性、成本效益和易用性,气泡式NCPAP(bNCPAP)应成为RDS新生儿的主要辅助技术。
评估将bNCPAP设备作为对需要通气辅助的新生儿的首要干预措施对院内新生儿死亡率的影响。
前瞻性干预前和干预后研究。
尼加拉瓜最大的新生儿重症监护病房(NICU)。
总共纳入了230名(2006年)和383名(2008年)患者。
2006年5月引入了一项策略,以促进对需要通气辅助的新生儿系统使用bNCPAP,避免插管和MV。收集了2006年5月至12月项目开始前以及两年后的2008年5月至12月期间接受辅助的婴儿的妊娠、分娩、产后病程、死亡率、住院时间和通气辅助时间等数据。
干预前后院内死亡新生儿的比例是主要终点。次要终点包括插管率和NICU住院时间。
插管率(72%对39%;p<0.0001)和仅接受bNCPAP治疗的患者比例(27%对61%;p<0.0001)存在显著差异。死亡率显著降低(40%对23%;p<0.0001);然而,观察到NICU平均住院时间有所增加(2006年为14.6天,2008年为17.5天,p=0.0481)。这些发现有助于证明NCPAP,尤其是bNCPAP,在中低收入国家患有呼吸窘迫的新生儿中,因其有效性、成本效益和易用性而成为一线标准治疗方法。
这是在中低收入国家的一个大型NICU中进行的首次广泛调查,证明了系统使用bNCPAP设备在降低新生儿死亡率方面的有效性。这些发现促使人们考虑将bNCPAP作为中低收入国家治疗呼吸功能不全新生儿的一种可选策略。